These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19839063)

  • 1. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation.
    Carrión JA; Torres F; Crespo G; Miquel R; García-Valdecasas JC; Navasa M; Forns X
    Hepatology; 2010 Jan; 51(1):23-34. PubMed ID: 19839063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis.
    Samonakis DN; Cholongitas E; Thalheimer U; Kalambokis G; Quaglia A; Triantos CK; Mela M; Manousou P; Senzolo M; Dhillon AP; Patch D; Burroughs AK
    Liver Transpl; 2007 Sep; 13(9):1305-11. PubMed ID: 17763383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation.
    Carrión JA; Navasa M; Bosch J; Bruguera M; Gilabert R; Forns X
    Liver Transpl; 2006 Dec; 12(12):1791-8. PubMed ID: 16823833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation.
    Blasco A; Forns X; Carrión JA; García-Pagán JC; Gilabert R; Rimola A; Miquel R; Bruguera M; García-Valdecasas JC; Bosch J; Navasa M
    Hepatology; 2006 Mar; 43(3):492-9. PubMed ID: 16496308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation.
    Carrión JA; Fernández-Varo G; Bruguera M; García-Pagán JC; García-Valdecasas JC; Pérez-Del-Pulgar S; Forns X; Jiménez W; Navasa M
    Gastroenterology; 2010 Jan; 138(1):147-58.e1. PubMed ID: 19786026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis.
    Lemoine M; Katsahian S; Ziol M; Nahon P; Ganne-Carrie N; Kazemi F; Grando-Lemaire V; Trinchet JC; Beaugrand M
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1102-10. PubMed ID: 18691352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
    Manousou P; Burroughs AK; Tsochatzis E; Isgro G; Hall A; Green A; Calvaruso V; Ma GL; Gale J; Burgess G; O'Beirne J; Patch D; Thorburn D; Leandro G; Dhillon AP
    J Hepatol; 2013 May; 58(5):962-8. PubMed ID: 23262247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
    Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
    HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
    Ghabril M; Dickson RC; Krishna M; Machicao V; Aranda-Michel J; Bonatti H; Nguyen JH
    Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
    Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
    Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation.
    Calvaruso V; Dhillon AP; Tsochatzis E; Manousou P; Grillo F; Germani G; Patch D; O'Beirne J; Burroughs AK
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1227-32. PubMed ID: 22432427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Cabrera R; Shuster JJ; Theriaque D; Reed AI; Hemming AW; Liu C; Crawford JM; Nelson DR
    Liver Transpl; 2004 Oct; 10(10):1240-7. PubMed ID: 15376304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection.
    do O NT; Eurich D; Schmitz P; Schmeding M; Heidenhain C; Bahra M; Trautwein C; Neuhaus P; Neumann UP; Wasmuth HE
    Liver Transpl; 2012 Mar; 18(3):298-304. PubMed ID: 22139994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation.
    Mariño Z; Mensa L; Crespo G; Miquel R; Bruguera M; Pérez-Del-Pulgar S; Bosch J; Forns X; Navasa M
    J Hepatol; 2014 Aug; 61(2):270-7. PubMed ID: 24703854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation.
    Harada N; Soejima Y; Taketomi A; Yoshizumi T; Ikegami T; Yamashita Y; Itoh S; Kuroda Y; Maehara Y
    Transplantation; 2008 Jan; 85(1):69-74. PubMed ID: 18192914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
    Berres ML; Trautwein C; Schmeding M; Eurich D; Tacke F; Bahra M; Neuhaus P; Neumann UP; Wasmuth HE
    Hepatology; 2011 Feb; 53(2):596-603. PubMed ID: 21274880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
    Alric L; Kamar N; Bonnet D; Danjoux M; Abravanel F; Lauwers-Cances V; Rostaing L
    Transpl Int; 2009 May; 22(5):568-73. PubMed ID: 19196449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.
    Manousou P; Dhillon AP; Isgro G; Calvaruso V; Luong TV; Tsochatzis E; Xirouchakis E; Kalambokis G; Cross TJ; Rolando N; O'Beirne J; Patch D; Thornburn D; Burroughs AK
    Liver Transpl; 2011 Feb; 17(2):178-88. PubMed ID: 21280191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C.
    Russo MW; Firpi RJ; Nelson DR; Schoonhoven R; Shrestha R; Fried MW
    Liver Transpl; 2005 Oct; 11(10):1235-41. PubMed ID: 16184580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.